Sensitizing tumours to immunotherapy: Development of an RNA-based therapeutic for pancreatic adenocarcinoma that targets the immunosuppressive tumour microenvironment.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1118168

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The blood vessels of tumours are highly abnormal resulting in leakiness and hypoxia within the microenvironment. These abnormalities contribute both to the pathology and also to resistance to treatment. We have developed a new drug that is able to inhibit vascular leak, better the response to therapies and improve disease outcome. This work will generate essential data for the development of this drug towards Clinical Trials through interaction with International Pharma.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2017

Funding Scheme: Development Grants

Funding Amount: $192,347.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Solid Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug development | endothelium | immunotherapy | microenvironment | microrna

Related Links